Compare Gilead Sciences, Inc. (GILD) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Jones Lang LaSalle Inc — how do they compare? Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B), while Jones Lang LaSalle Inc trades at $364.99 (market cap $16.72B). The key difference: Gilead Sciences, Inc. is far larger — about 10.1× Jones Lang LaSalle Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| GILD | JLL | |
|---|---|---|
Market Cap | $168.35B | $16.72B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $373.24 |
52-Week Low | $110.56 | $280.16 |
Enterprise Value | $191.42B | $19.48B |
Dividend Yield | 2.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
